Clinical trials: insulin glargine
Diabetes Mellitus Type 2
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Primary Objective: To demonstrate the ease of use of the U300 pen injector in pen-naïve and insulin-naïve type 2 diabetes mellitus (T2DM) patients in a 4-week once-daily dosing regimen with HOE901-U300.
- Trial name
- NCT02227212
- Testing
- Insulin glargine U300 (new formulation of insulin glargine) HOE901
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Sanofi
Cardiovascular Events, Type2 Diabetes
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose…
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Trial name
- CER-4-T2D (NCT05220917)
- Testing
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA
- Where
- United States
- Volunteers
- 781,430 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes
New Onset Type 1 Diabetes: Role of Exenatide
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to treat people with type 2 diabetes which helps…
- Trial name
- NCT01269034
- Testing
- Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Diabetes Mellitus, Type 2
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
Primary objective: To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients Secondary objectives: To assess the forced titration on physician and patient satisfaction To evaluate…
- Trial name
- LANTIT (NCT00701831)
- Testing
- Insulin glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Primary objective: To show an improvement in HbA1c control after 4 months of treatment with insulin glargine + Oral Anti Diabetic (OAD) in patients previously uncontrolled on premixed insulin (with OAD) Secondary objective…
- Trial name
- OPTIMIZATION (NCT00693771)
- Testing
- Insulin Glargine
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
- Trial name
- NCT00664534
- Testing
- Insulin Glargine, Insulin Lispro Premix (mid-mixture and low-mixture)
- Where
- 27 sites in Canada, Egypt and 6 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Diabetes, Hyperglycemia
Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the…
- Trial name
- NCT00394407
- Testing
- sliding scale regular insulin, glargine basal insulin and glulisine prandial insulin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Emory University
Type 2 Diabetes
A Comparison of Exenatide and Insulin Glargine
This is a 16-week, Single-center, Randomized, Open Label, Parallel Controlled Group Comparison of the Comprehensive Glycemic Control of Exenatide and Insulin Glargine on Type 2 Diabetes Patients Inadequately Controlled With…
- Trial name
- NCT02325960
- Testing
- exenatide, Insulin glargine
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Type 2 Diabetes
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. The main study will last 32 weeks.
- Trial name
- MEXELIN (NCT00667732)
- Testing
- exenatide
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Type 1 Diabetes
Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes
Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin.
- Trial name
- NCT00276393
- Testing
- Basal insulin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who…
- Trial name
- NCT01278160
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
In this pilot study we are evaluating the efficacy of pramlintide on preventing weight gain among early onset type 1 diabetes. We are also evaluating the safety and the effects of treatment with pramlintide on early diagnosed…
- Trial name
- NCT00505882
- Testing
- Pramlintide, Glargine, Lispro
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus Type 2
Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Diabetes mellitus is a wide-spread disease accompanied by strongly increased morbidity and mortality due to micro- and macrovascular complications.
- Trial name
- ELMI (NCT02752113)
- Testing
- Empagliflozin and Linagliptin, Metformin and Insulin sc
- Where
- Germany
- Volunteers
- 101 people
- Sponsor
- Institut für Pharmakologie und Präventive Medizin
Diabetes, Diabetes Mellitus, Type 1
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
This trial iss conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01002768
- Testing
- insulin degludec, insulin glargine
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of…
- Trial name
- NCT02229227
- Testing
- Albiglutide, Insulin Glargine and Insulin Lispro
- Where
- 157 sites in United States, Brazil and 12 more
- Volunteers
- 814 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
The primary study objective was to compare the rate of "all hypoglycemia" (composite outcome of the following hypoglycemia events: symptomatic hypoglycemia episodes, low continuous glucose monitoring system (CGMS) excursions…
- Trial name
- PRESCHOOL (NCT00993473)
- Testing
- Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
- Where
- 61 sites in United States, Austria and 14 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)
This study evaluates in a group of people with DM 1 the influence in parameters of oxidative stress of the treatments with the different current analogs of insulin
- Trial name
- INEOX (NCT03328845)
- Testing
- Toujeo SoloStar, Tresiba, Humalog Kwikpen
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Diabetes Mellitus
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
- Trial name
- NCT01910194
- Testing
- Luyxumia versus Lantus
- Where
- 2 sites in Germany
- Volunteers
- 39 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH